- Home
- BTDR vs SLS Comparison
BTDR vs SLS Comparison
Compare BTDR & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BTDR | SLS |
|---|---|---|
| Founded | 2021 | 2012 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.7B |
| IPO Year | 2021 | 2007 |
Fundamental Metrics
Financial Performance| Metric | BTDR | SLS |
|---|---|---|
| Price | $10.62 | $11.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 2 |
| Target Price | $21.79 | ★ $32.50 |
| AVG Volume (30 Days) | ★ 8.5M | 5.0M |
| Earning Date | 11-09-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $50.36 | N/A |
| Revenue Next Year | $66.80 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.04 | $1.39 |
| 52 Week High | $27.80 | $15.88 |
Technical Indicators
Market Signals| Indicator | BTDR | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 41.89 | 49.35 |
| Support Level | $8.58 | $10.82 |
| Resistance Level | $13.08 | $15.77 |
| Average True Range (ATR) | 0.74 | 0.75 |
| MACD | -0.22 | 0.02 |
| Stochastic Oscillator | 1.76 | 79.10 |
Price Performance
Historical ComparisonAbout BTDR Bitdeer Technologies Group
Bitdeer Technologies Group is principally engaged in the provision of digital asset mining services. The Company does not conduct any substantive operations on its own but conducts its primary operations through its subsidiaries. Its majority business segments are: proprietary mining, cloud hash rate sharing and cloud hosting. The company operates five proprietary mining datacenters in the United States and Norway, Bhutan and Singapore.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.